Abbott's XIENCE PRIME(TM) and XIENCE V® Drug Eluting Stents Receive Indication ... MarketWatch (press release) PARIS, May 15, 2012 /PRNewswire via COMTEX/ -- Abbott (NYSE:ABT) today announced that the XIENCE PRIME(TM) and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for ... Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in ... |
